Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on SEVERFIELD PLC. We currently have 6 research reports from 1 professional analysts.
|20Feb17 16:23||RNS||Holding(s) in Company|
|17Feb17 13:21||RNS||Director/PDMR Shareholding|
|14Feb17 14:29||RNS||Holding(s) in Company|
|24Jan17 15:30||RNS||Holding(s) in Company|
|19Jan17 16:26||RNS||Holding(s) in Company|
|17Jan17 09:53||RNS||Director/PDMR Shareholding|
|04Jan17 15:18||RNS||Total Voting Rights|
Frequency of research reports
Research reports on
07 Dec 16
Severfield’s (SFR’s) H117 results were well ahead of the previous year; margin performance and order book development cause us to raise our FY17 profit expectations. This combination has also proved to be a catalyst for share price outperformance following the results. Revenue growth and further margin development towards management’s stated aim of doubling FY16 PBT by 2020 can sustain further progress.
Margin targets met, new goals set
18 Jul 16
The achieved FY16 margin was as an ambitious target when set in 2013, but is now seen as a staging post to the new aim of doubling PBT by FY20. Our revised estimates track towards this. With double-digit earnings progress expected (and a PEG below 1x), plus a rising dividend profile, Severfield now clearly offers both income and capital growth attractions.
Set to outperform
03 May 16
Severfield’s rising UK order book and improving margins set a good tone ahead of FY16 results on 15 June. A recent capital markets event served to reinforce the margin development path that the company is on, with further progress targeted. Little of this appears to be factored into the share price currently and we believe the scope for outperformance is now significant.
Significant increase in UK order book
18 Feb 16
An in-line trading update states that Severfield’s UK and Indian JV operations and the group overall are performing as outlined in the H116 results. Both regions have seen improved order book positions, with a 33% increase in the UK since the beginning of November particularly noteworthy. While some cautionary industry comments were reiterated, we consider that the UK order position is a strongly positive development.
Margin momentum building
07 Dec 15
Severfield's delivery of higher margins is on track and operational improvements made are bedding in as some sector indicators are looking increasingly positive. Save for nudging up our dividend expectations, we have left estimates unchanged at this stage. We believe that improved order newsflow is in prospect and could become the share price driver.
Well positioned in improving markets
20 Oct 15
A recent in-line AGM statement and signs of improving sector demand both support expectations of further progress from Severfield. Order book levels and mix will be an important indicator of near term prospects but we believe that delivery of better margin on a rising revenue trend over the course of FY16 will bring mid-cycle prospects more into view. For now, the company rating reflects a still relatively early-stage earnings recovery.
20 Feb 17
Hayward Tyler Group* (HAYT): Trading update and financial position (CORP) | Petra Diamonds (PDL): Interim results (BUY) | Gemfields* (GEM): Interim results (CORP) | Premaitha Health* (NIPT): Middle East momentum (CORP) | Sound Energy (SOU): Acquisition update and TE-8 well spud (HOLD) | Proactis* (PHD): Interim trading on track (CORP) | 7digital* (7DIG): Automotive contract win (CORP)
21 Feb 17
Lighthouse Group* (LGT): Middle Britain growth (CORP) | Utilitywise* (UTW): Double-digit sales growth (CORP) | Trakm8* (TRAK): Earnings expectations cut again (CORP) | dotDigital* (DOTC): Myriad growth opportunities (CORP) | Artilium* (ARTA): Five-year Telenet deal secured and prepaid (CORP) | Netcall* (NET): Cloud investment pays off (CORP)
N+1 Singer - Small-cap quantitative research - New quality style screen + 11 quality focus stocks
09 Feb 17
We introduce our fourth and final style screen representing “quality”. This screens for stocks with the best combination of high returns on capital/equity, EBIT margins and operating cash-flow conversion rates. These criteria should help us monitor how strong underlying returns translate into share price performance over time and under varying market conditions. The screen selects the “best” 25 stocks from our universe of just over 500 stocks and, as usual, we focus on a shorter list of stocks we cover or otherwise know and believe to be particularly interesting. We provide brief investment summaries on these focus stocks on pages 4 – 9. We will monitor performance and refresh the screen in approximately 3-4 months time.
The Slide Rule
12 Jan 17
What is The Slide Rule? The Slide Rule has been designed to dramatically simplify the identification of the best companies in the UK small/mid-cap sector by making a quantitative assessment of the relative potential of each company. At its core, The Slide Rule aims to identify those companies that create genuine shareholder value through strong returns on capital and solid growth, but also present a value opportunity with the potential tailwind of earnings momentum. Companies are assessed within a Quality, Value, Growth and Momentum (QVGM) framework.
Time to go over weight
24 Feb 17
We believe equity investors are taking an unnecessarily cautious stance on the construction sector. Forward looking indicators (e.g. consumer confidence, construction PMIs and housing starts) point to a stable market and recent sales LFL are particularly encouraging (e.g. Marshalls). Near term margins may suffer temporary distortions as inflationary pressures build. However, history has shown that modest input cost inflation is actually a positive for earnings growth in the sector. Therefore, as we move into 2018, margin trends are likely to surprise on the upside.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced